Premium
Possible inhibition of hepatic metabolism of quinidine by erythromycin
Author(s) -
Spinler Sarah A.,
Cheng Judy W. M.,
Kindwall K. Elizabeth,
Charland Scott L.
Publication year - 1995
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1016/0009-9236(95)90270-8
Subject(s) - quinidine , erythromycin , pharmacology , drug interaction , medicine , pharmacokinetics , torsades de pointes , antibiotics , chemistry , qt interval , biochemistry
Objective To present and analyze a patient case illustrating a possible drug interaction between quinidine and erythromycin. Methods This is a case report of one hospitalized patient. The setting for this analysis was a university hospital. Through a MEDLINE search of all English medical literature (1966 to 1994) documenting possible interactions between quinidine and erythromycin, retrospective patient chart review, and analysis of the relationship between serum quinidine concentrations and significant clinical events, deduce the possibility of a quinidine and erythromycin pharmacokinetic and pharmacodynamic interaction in this particular patient case. Results This case demonstrated a probable erythromycin‐quinidine pharmacokinetic interaction that led to a decrease in quinidine apparent clearance, an increase in quinidine serum concentrations, and a possible quinidine toxicity. Conclusion Serum quinidine concentrations, electrocardiograms, and other factors that may predispose patients to torsades de pointes, such as hypokalemia and hypomagnesemia, should be monitored closely if quinidine is coadministered with erythromycin. Clinical Pharmacology & Therapeutics (1995) 57 , 89–94; doi: